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In worldwide studies, interleukin-6 (IL-6) is implicated in age-related disturbances. The aim of the present report was to
determine the possible association of IL-6 -174 C/G promoter polymorphism with the cytokine profile as well as with the presence
of selected cardiovascular risk features. This was a cross-sectional study on Brazilian women aged 60 years or older. A sample
of 193 subjects was investigated for impaired glucose regulation, diabetes, hypertension, and dyslipidemia. Genotyping was
done by direct sequencing of PCR products. IL-6 and C-reactive protein were quantified by high-sensitivity assays. General
linear regression models or the Student t-test were used to compare continuous variables among genotypes, followed by
adjustments for confounding variables. The chi-square test was used to compare categorical variables. The genotypes were
consistent with Hardy-Weinberg equilibrium proportions. In a recessive model, mean waist-to-hip ratio, serum glycated
hemoglobin and serum glucose were markedly lower in C homozygotes (P = 0.001, 0.028, and 0.047, respectively). In a
dominant hypothesis, G homozygotes displayed a trend towards higher levels of circulating IL-6 (P = 0.092). Non-parametric
analysis revealed that impaired fasting glucose and hypertension were findings approximately 2-fold more frequent among G
homozygous subjects (P = 0.042 and 0.043, respectively). Taken together, our results show that the IL-6 -174 G-allele is
implicated in a greater cardiovascular risk. To our knowledge, this is the first investigation of IL-6 promoter variants and age-
related disturbances in the Brazilian elderly population.
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INTRODUCTION
Inflammation is recognized as a central component of
cardiovascular disease (CVD), even though the underly-
ing regulation and molecular mechanisms remain unclear
(1). Interleukin-6 (IL-6) is a pleiotropic cytokine involved in
a range of immunological activities, especially the synthe-
sis of acute-phase substances by the liver. As its receptor
subunit (gp130) is widely expressed, deregulated high-
level production of the cytokine combined with its agonistic
soluble receptor (sIL-6R) may induce an undesired basal
inflammatory state in many organs and thus cause non-
communicable diseases (2). It has been reported that the
common -174 C/G polymorphism in the promoter region of
human IL-6 regulates its transcription in vitro, with the G
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allele showing increased transcriptional activity both under
basal conditions and in response to inflammatory stimuli
such as lipopolysaccharides or IL-1 (3-5). However, data
on the effects of this polymorphism on IL-6 levels in vivo
have led to conflicting results. Most studies have shown
that G/G individuals have an increased IL-6 mRNA expres-
sion (6) and higher circulating IL-6 levels (3,7), as would be
expected from in vitro data. Conversely, other studies have
reported no differences among genotypes or increased
levels of the cytokine among C/C-carrying subjects (8,9).
In addition to the issue of genotype-related expression
levels, it is also recognized that an age-related increase in
serum IL-6 levels takes place among men and women
(10), beginning as early as at 30-40 years of age (11),
being prevalent even in people devoid of any overt acute or
chronic disease (12), becoming prominent in later life
(13,14), and acting as a predictor of mortality independent
of pre-existing morbidity (15).
By and large, elevated levels of IL-6 are associated
with an increased risk of death from cardiovascular causes
in the elderly. Elevated levels of C-reactive protein (CRP),
an acute-phase reactant largely regulated by IL-6, are also
independently associated with a long-term risk for CVD
(16). Our underlying hypothesis is that IL-6 genotypes may
predispose to risk factors for CVD (hypercholesterolemia,
hypertriglyceridemia, hypertension, diabetes, and impaired
glycemic homeostasis) which would then be accompanied
by a chronic inflammatory disorder. The existence of link-
age disequilibrium between -174 C/G polymorphism and
other genotypes, revealed by Western-based population
haplotyping studies (5,17), demonstrates that investigat-
ing solely the -174 C/G polymorphism is as informative as
investigating the entire promoter haplotype. Because a
large fraction of cardiovascular events occurs in people
aged 60 years or older and the IL-6 promoter polymor-
phism has not been studied extensively among aged
women, we examined the effects of the -174 C/G geno-
types on CVD risk factors in a subset of subjects from the
Elderly Health Promotion Project held in Brasília, Brazil.
MATERIAL AND METHODS
Subjects
Brasília is the administrative capital of the Brazilian
federation, located in Central West Brazil. Sampling for the
present study was based on preliminary genotyping of 30
subjects. A minimum series of 175 subjects was deter-
mined for a frequency of risk allele of 0.80, with a confi-
dence level of 0.95 and an estimation error of 0.05 for a
finite population. Therefore, cross-sectional analyses were
performed using data obtained from 224 apparently healthy,
female outpatients from the urban outskirts of the Brazilian
Federal District, aged 60 years or older and recruited to
undergo health screenings and intervention (medical, nu-
tritional and/or pharmacological) for the prevention of CVD
at the Hospital of Universidade Católica de Brasília. For
recruitment purposes, public invitations through mass com-
munication networks were broadcast early in 2005. Invita-
tions were directed at aged women from the outskirts of
Brasília invited to join a university research project involv-
ing health promotion actions and ambulatory follow-up.
The project became known as the Elderly Health Promo-
tion Project, and this is the first report of our activities in the
project. The assessment on cardiovascular risk reported in
this study was performed from April to October 2005. The
study was approved by the institutional Research Ethics
Committee (CEP/UCB). Participation was voluntary, and
informed written consent was obtained from each partici-
pant in accordance with the principles of the Helsinki
Declaration.
Clinical procedures
Laboratory tests included serum liver tests (aspartate
aminotransferase, alanine aminotransaminase, and alka-
line phosphatase), cytomegalovirus and Epstein-Barr IgM
serology, and total blood count. Fasting serum determina-
tions of glucose, glycated hemoglobin (HbA1c), triglyceri-
des, total cholesterol, and fractions (low- and high-density
lipoprotein) were also obtained. All tests were performed
following routine clinical analysis. CRP was measured
using a high-sensitivity turbidimetric assay (BioTécnica®,
Varginha, MG, Brazil) with a sensitivity of 0.05 mg/L.
For IL-6 measurement, whole blood was collected into
endotoxin-free tubes. Serum was separated from whole
blood within 1 h of collection, stored in aliquots at -80°C
and analyzed in batches using a specific enzyme-linked
immunosorbent assay kit (GE Healthcare, Uppsala, Swe-
den). Samples for IL-6 quantification were analyzed in
duplicate and their coefficient of variation (CV) were deter-
mined (CVC/C 11.7 vs 15.6; CVG/C 29.6 vs 26.3; CVG/G 66.4
vs 84.7). The minimum detectable dose was 0.10 pg/mL.
On the occasion of the clinical visit, blood pressure was
measured after at least 10 min of rest in the sitting position.
The blood pressure value of each subject was the mean of
three physician-obtained measurements, recorded >3 min
apart. Body mass index (BMI; weight (kg)/height (m²)) and
waist-to-hip ratio (WHR; waist circumference/hip circum-
ference) were obtained for each patient. Body weight was
measured to the nearest 0.1 kg with the subject using light
clothing and without shoes and height was measured to
the nearest 0.1 cm. Waist circumference was measured
midway between the iliac crest and the lower costal mar-
gin, whereas hip circumference was measured at its maxi-
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mum. Cases of active infection, inflammation or malignan-
cies were assessed by semiological criteria based on
medical examination assisted by laboratory data.
Hypertension was defined as systolic blood pressure
≥135 or diastolic blood pressure ≥85 mmHg, or current use
of antihypertensive medication, whereas diabetes mellitus
was characterized by fasting blood glucose ≥126 mg/dL, or
current use of insulin or oral anti-diabetic drugs. Impaired
glucose regulation encompassed cases of diabetes melli-
tus and any cases of fasting blood glucose ≥110 mg/dL.
Hypertriglyceridemia was defined as triglycerides ≥150
mg/dL and hypercholesterolemia was defined as total
cholesterol ≥200 mg/dL or low-density lipoprotein ≥130
mg/dL. Current use of anti-lipemic medication was consid-
ered to represent either entity. Dyslipidemia was defined
as isolated or combined hypertriglyceridemia, hypercho-
lesterolemia and high-density lipoprotein <50 mg/dL.
DNA analysis
Total DNA was isolated from peripheral blood accord-
ing to standard procedures. The -174 G/C polymorphism in
the promoter of the human IL-6 gene (rs1800795) was
determined by direct sequencing of a polymerase chain
reaction product. A 628-bp region was amplified using a
pair of specific primers: 5'-GAACACAGAAGAACTCAGATG
ACTGG-3' (sense) and 5'-AGGAGTTCATAGCTGGGCTC
CTGGAG-3' (antisense), which flank the polymorphism.
The reaction tubes contained 100 ng DNA, 10 mM Tris-
HCl, pH 9.2, 25 mM KCl, 1.5 mM MgCl2, 0.2 mM dNTP, 20
pmol of each primer, 0.5 µg purified chicken albumin, and
1 unit Taq DNA polymerase (Phoneutria®, Belo Horizonte,
MG, Brazil) in a final volume of 50 µL. After 1 min of hot start
at 80°C and an initial denaturation for 2 min at 94°C, the
amplifications were carried out for 36 cycles of 40 s at
94°C, 45 s at 64°C, and 50 s at 72°C followed by a final 5-
min extension at 72°C. Each polymerase chain reaction
product was directly sequenced on an ABI PRISM 3700
DNA analyzer (Applied Biosystems, Foster City, CA, USA),
using the 5'-GCCTCAGAGACATCTCCAGTCC-3' primer.
Each sequence obtained was examined using the Staden
software package (MRC, Cambridge, UK), and confirmed
by visual inspection.
Statistical analysis
Violation of Hardy-Weinberg equilibrium was tested
using the Fisher exact test. The Kolmogorov-Smirnov test
was used to determine the distribution of data from con-
tinuous variables. Whenever appropriate, data were re-
ported as means ± SD. General linear regression models
or the Student-t test were used to compare means of
continuous variables (levels of fasting glycemic markers,
blood pressure, white blood cell count, lipids, liver mark-
ers, CRP, and IL-6) across genotypes using dominant, co-
dominant and recessive comparison models. Post hoc
comparisons were made using the Tukey test for pairwise
comparisons. Phenotypic differences between genotypes
were also tested for influence of co-variables by adjust-
ment for confounding factors (age and BMI) by ANOVA.
Association of IL-6 genotypes with categorical vari-
ables representing CVD risk factor (states of impaired
glucose regulation, diabetes, hypertension, and dyslipide-
mia) was investigated by the χ2 test. All analyses were
performed employing the Statistical Package for Social
Sciences (SPSS) for Windows (version 10.0). A P value <
0.05 was considered to be significant.
RESULTS
Data from 31 individuals enrolled in the clinical screen-
ing were eliminated from the databank due to exclusion
reasons described as follows: 17 for unavailability for
laboratory testing, 12 for current use of anti-inflammatory
drugs, and 2 for cytomegalovirus or Epstein-Barr reactiv-
ity. No subjects were excluded based on the criteria of
active infection, inflammation or malignancy. Therefore,
193 subjects fulfilling the inclusion criteria were included.
The prevalence of the IL-6 -174 G and C alleles was
78.9 and 21.1%, respectively. The genotypes were con-
sistent with Hardy-Weinberg equilibrium proportions (61.9%
G/G, 34.0% C/G, 4.1% C/C; P > 0.05). The clinical and
laboratory characteristics of the subjects analyzed are
summarized in Table 1. In a co-dominant model, no signifi-
cant differences in age, BMI, fasting glucose levels, HbA1c
levels, serum lipids, liver marker concentration, leukocyte
count, or CRP were observed between subjects carrying
the three genotypes. Nonetheless, the mean WHR was
significantly reduced in subjects carrying the -174 C/C
genotype compared to carriers of the G/G (P = 0.004) and
C/G (P = 0.001) genotypes, concurring with a recessive
model of genotype effect. In agreement, homozygous car-
riers of the C allele also had significantly lower levels of
fasting serum glycated hemoglobin and glucose com-
pared to carriers of the G allele (Table 1). To explore a
dominant hypothesis, analysis combining the C/G and C/C
genotypes in one group was also performed. In this sce-
nario, the mean WHR and average glycemic markers did
not differ significantly between the G homozygotes and the
C carriers. By contrast, a tendency towards higher serum
IL-6 levels was observed among G homozygotes com-
pared to carriers of the C allele (P = 0.092).
Because of the possible association of IL-6 expres-
sion, glycemic levels and WHR with variables such as age
and adiposity, differences between genotypes were inves-
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Table 1. Clinical and biochemical data as a function of the -174 G/C genotypes of the IL-6 gene in 193 older Brazilian women.
G/G G/C C/C P (G/G vs P (G/G vs P (C/C vs
(N = 119) (N = 66) (N = 8) C/G vs C/C )* C/G + C/C )** C/G + G/G )***
Age (years) 68.8 ± 6.2 67.4 ± 5.3 66.1 ± 3.4 0.185 0.067 0.313
Body mass index (kg/m2) 26.9 ± 4.0 27.0 ± 4.2 28.1 ± 3.1 0.753 0.781 0.453
Waist-to-hip ratio 0.88 ± 0.08 0.90 ± 0.08 0.79 ± 0.28 0.001 0.721 0.001
Fasting glucose (mg/dL) 105.2 ± 32.2 106.7 ± 31.7 91.4 ± 8.2 0.121a 0.989a 0.047b
Fasting glycated hemoglobin (%) 5.6 ± 0.6 5.7 ± 0.6 5.2 ± 0.5 0.083 0.854 0.028
Total cholesterol (mg/dL) 230.0 ± 45.2 230.0 ± 45.2 216.6 ± 37.9 0.544 0.736 0.355
HDL cholesterol (mg/dL) 61.0 ± 9.9 61.9 ± 10.6 63.1 ± 9.8 0.279 0.506 0.623
LDL cholesterol (mg/dL) 138.8 ± 39.9 138.5 ± 40.3 127.0 ± 32.8 0.332 0.797 0.416
Triglycerides (mg/dL) 149.2 ± 72.0 152.9 ± 64.6 131.2 ± 72.9 0.703 0.900 0.442
Systolic blood pressure (mmHg) 137.5 ± 26.0 140.7 ± 28.7 126.2 ± 29.2 0.336 0.688 0.206
Diastolic blood pressure (mmHg) 82.1 ± 16.6 81.4 ± 13.9 76.2 ± 16.8 0.594 0.589 0.327
Aspartate aminotransferase (U/L) 25.4 ± 7.4 25.2 ± 7.4 25.5 ± 7.2 0.980 0.874 0.940
Alanine aminotransferase (U/L) 20.3 ± 12.5 19.8 ± 9.6 19.8 ± 7.4 0.947 0.742 0.924
Alkaline phosphatase (U/L) 194.6 ± 74.7 189.2 ± 74.7 171.1 ± 69.7 0.648 0.502 0.423
White blood cell count (x 109/mL) 4.5 ± 1.7 4.5 ± 1.7 4.3 ± 1.0 0.933 0.995 0.721
C-reactive protein (mg/L) 2.2 ± 2.8 2.4 ± 3.2 2.2 ± 2.0 0.926a 0.870b 0.699b
Fasting interleukin-6 (pg/mL) 1.16 ± 3.84 0.39 ± 1.36 0.00 ± 0.00 - 0.092b -
Data are reported as means ± SD.
*P values for comparison of differences between genotypes in a co-dominant model (GG vs GC vs CC ) using ANOVA or the aKruskal-
Wallis test. **P values for comparison of differences between genotypes in a dominant (GG vs CG + CC ) model using the unpaired
Student t-test or bMann-Whitney test. ***P values for comparison of differences between genotypes in a recessive (GG + CG vs CC )
model using the unpaired Student t-test or bMann-Whitney test.
tigated by adjusting to these confounding factors. In brief,
all significant differences described so far resisted adjust-
ment for age and BMI, while no other difference in bio-
chemical or clinical quantitative traits became significant
after correction (data not shown). CRP levels showed
nonsignificant variance in either model, adjusted or not to
age and adiposity. This homogeneity persisted after addi-
tional adjustment to markers of liver status (aspartate
aminotransferase, alanine aminotransaminase and alka-
line phosphatase).
In order to study the association of -174 G/C polymor-
phism with clinically established risk parameters for CVD,
we performed non-parametric analysis to evaluate the
difference in distribution of hypercholesterolemia, hypertri-
glyceridemia, hypertension, diabetes, and impaired glu-
cose regulation among genotypes. Due to the low number
of homozygous individuals for the C allele, the genotype
was merged with the heterozygous subjects for the cat-
egorical analysis. According to this dominant model (GG
vs GC + CC), G homozygous subjects were roughly twice
as much affected by impaired fasting glucose metabolism
and hypertension compared to the C-carrier counterparts
(Table 2). In the present study, we did not observe a trend
towards an association between genotypes and serum
lipid disturbances.
DISCUSSION
Increasing evidence suggests that low-grade inflam-
mation could be one of the determinants of an unbalanced
glucose handling capacity and blood pressure disorders
(18,19). The implication of IL-6 promoter polymorphisms in
prominent transcriptional effects on the gene (3) makes
these variations credible candidates for association with
chronic disorders.
The aim of the present study was to determine a
possible association of the IL-6 -174 C/G promoter poly-
morphism with the amount of cytokine released in the
serum of older female adults from the Brazilian population,
as well as with the presence of selected biochemical or
clinical features representative of cardiovascular risk in
this age stratum. Regardless of any age-related up-regula-
tion of plasma IL-6 levels, the data presented here suggest
a tendency to greater in vivo release of the cytokine among
aged individuals carrying the IL-6 -174 G/G genotype.
Thus, an underlying lesson is that it may be important to
take into account IL-6 genotypes whenever comparisons
of cytokine production are performed between different
age strata.
We suggest that the quantitative findings presented so
far may be of physiological relevance. The association
between G homozygosis and CVD-prone conditions (im-
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paired fasting glucose and hypertension) is consistent with
a dominant model of genotype effect. On the other hand,
the relationship of C homozygosis with lower WHR, HbA1c
and serum glucose suggests that a recessive model of
genotype effect is advantageous at clinical level. Regard-
less of the exact model, our results, taken together, assign
a determining effect to the G allele. Previous investigations
with Western populations also consider the -174 G allele
as the risk allele. The largest meta-analysis on genetics of
type 2 diabetes among Caucasians published to date
provides evidence for an association of the disorder with
the G/G genotype (20). In Pima Indians (21) and in Native
American and Spanish (22) admixed populations, the G
allele was also associated with type 2 diabetes. Fernandez-
Real and colleagues (23) found higher blood HbA1c in
carriers of the G allele, while other studies found that
carriers of the G-variant allele had lower glucose handling
capacity in insulin sensitivity assays (6,24). The present
study also reveals a tendency to an increased frequency of
the hypertensive phenotype among G/G homozygotes. To
the authors’ knowledge, blood pressure might be influ-
enced by IL-6 expression but a smaller body of evidence is
supportive for an association between hypertension and
low-grade inflammation in the female gender (25). Thus,
the observed association may represent an accentuation
of the phenotype due to the age stratum of the sample.
The lack of association between genotypes and other
markers of the acute phase response (namely CRP and
peripheral leukocyte count) suggests that clinical outcomes
of IL-6 levels may derive from endocrine rather than immu-
nological effects of this pleiotropic cytokine. The mechan-
isms by which the G allele might cause an increased WHR
are unknown, but this allele might act as a triggering agent
of the dose-dependent lipolytic effect of IL-6 on peripheral
storages (26) driving to fat mobilization toward the abdomi-
nal compartment. According to a vicious cycle hypothesis,
IL-6 secreted from the abdominal adipose tissue in a non-
inflammatory condition (27) would flow by venous drain-
age directly into the liver and drive a persistent increase in
hepatic triglyceride secretion (28,29), intensifying the phe-
notype.
Regarding the association between G homozygotes
and aspects of an unbalanced glucose regulation, it is
known that insulin attenuates several stimulatory effects of
IL-6 (30,31). Thus, the lack of a significant insulin action,
as found in type 2 diabetes, would lead to prolonged
detrimental effects of the cytokine (32). In addition, it has
been demonstrated that increased levels of IL-6 impair
insulin signaling in models using human cells, such as
adipocytes and hepatocytes, by a mechanism that in-
volves at least in part an up-regulation of the inhibitory
suppressor of cytokine signaling-3 (33,34). Again, accord-
ing to a vicious cycle hypothesis, genetically prone produc-
ers of IL-6 such as G/G individuals may be predisposed to
intensification of an insulin-resistant state initiated by inap-
propriate food intake and life style.
 The present results are in contrast to reports showing
a significant relationship between the G/G genotype and
different lipidemia-related (serum lipids and BMI) pheno-
types (23,35). We have no simple explanation for this
discrepancy. Obviously, any apparent disparity in results
might be attributable in part to interethnic variation owing to
the remarkable Brazilian genetic admixture (36), as well as
to food intake habits not investigated here. As stated
before, no other inflammatory markers differed among
genotypes, in contrast to reports based on western elderly
populations. Regarding total (Table 1) and differential (not
shown) white blood cell counts, described elsewhere as
genotype-influenced factors (23), no higher or lower counts
Table 2. Frequency distribution of the IL-6 -174 G/C genotypes
in different conditions that represent cardiovascular risk factors,
according to a dominant model.
Frequencies*
Condition G/G G/C + C/C  χ2 P
(N = 119) (N = 74)
Blood pressure




Regular 67.2 79.7 3.54 0.042
Impaired 32.8 20.3
Ratio 0.5 0.2












≥50 mg/dL 77.3 77.0 0.00 0.964
<50 mg/dL 22.7 23.0
Ratio 0.3 0.3
Lipidemia
Normolipemic 14.3 12.2 0.18 0.674
Dyslipemic 85.7 87.8
Ratio 6.0 7.2
*Frequencies are expressed as percentage within the genotype.
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could be associated with either hereditary model under our
conditions. Also in disagreement with the literature (37), no
variance in CRP levels was observed among genotypes.
Although increased IL-6 levels were not paralleled by CRP
levels in the various genotypes, the present study yields
the assumption that baseline levels of the cytokine are
more predictive of cardiovascular events than levels of the
acute-phase reactant.
The present study has limitations. We have not been
able to genotype other potentially functional (coding and
non-coding) variations in the IL-6 locus so that such inter-
ference could be ruled out. Since the study was carried out
on a female series, the authors are reticent in extrapolating
conclusions to male counterparts, since the literature dem-
onstrates significant gender-dependent predisposition to
increased IL-6 serum levels in aging women, but not in
men (38,39).
To our knowledge, this is the first investigation of whether
the IL-6 promoter variants –174 G/C are linked to age-
related metabolic disturbances in the Brazilian elderly popu-
lation. Our results suggest that this functional polymor-
phism influences circulating IL-6 levels, and indicate a
contribution of the G allele to a glucose-intolerant and a
hypertensive state as well to an increased WHR in post-
menopausal women. The present study does not support
associations with further age-related disorders. Whether
this polymorphism is a risk factor for obesity or type 2
diabetes could be estimated only in prospective popula-
tion-based studies. In conclusion, we demonstrated that
the -174 C/G promoter polymorphism of the IL-6 gene is
unequivocally associated with several features consistent
with cardiovascular risk in apparently healthy elderly Bra-
zilian females. Immunogerontological avenues of investi-
gation on the effect of cytokine genes and levels in dis-
eases of aging are appropriate for this population.
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